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ABSTRACT
The invasive nature of surgical biopsies deters sequential application, and single 
biopsies often fail to reflect tumor dynamics, intratumor heterogeneity and drug 
sensitivities likely to change during tumor evolution and treatment. Implementing 
molecular characterization of cell-free neuroblastoma-derived DNA isolated from blood 
plasma could improve disease assessment for treatment selection and monitoring of 
patients with high-risk neuroblastoma. We established droplet digital PCR (ddPCR) 
protocols for MYCN and ALK copy number status in plasma from neuroblastoma 
patients. Our ddPCR protocol accurately discriminated between MYCN and ALK 
amplification, gain and normal diploid status in a large panel of neuroblastoma cell 
lines, and discrepancies with reported MYCN and ALK status were detected, including 
a high-level MYCN amplification in NB-1, a MYCN gain in SH-SY5Y, a high-level ALK 
amplification in IMR-32 and ALK gains in BE(2)-C, Kelly, SH-SY5Y and LAN-6. MYCN 
and ALK status were also reliably determined from cell-free DNA derived from 
medium conditioned by the cell lines. MYCN and ALK copy numbers of subcutaneous 
neuroblastoma xenograft tumors were accurately determined from cell-free DNA in 
the mouse blood plasma. In a final validation step, we accurately distinguished MYCN 
and ALK copy numbers of the corresponding primary tumors using retrospectively 
collected blood plasma samples from 10 neuroblastoma patients. Our data justify the 
further development of molecular disease characterization using cell-free DNA in blood 
plasma from patients with neuroblastoma. This expanded molecular diagnostic palette 
may improve monitoring of disease progression including relapse and metastatic 
events as well as therapy success or failure in high-risk neuroblastoma patients.
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INTRODUCTION
Neuroblastoma, an embryonal tumor of 
neuroectodermal origin, accounts for 11% of all cancer-
related deaths in children [1]. Molecular aspects create 
the extreme heterogeneity of this disease, spanning 
spontaneous regression to rapid metastasizing progression 
[2, 3]. Treatment scenarios range between observation 
only and multimodal concepts including high-dose 
chemotherapy with autologous stem cell rescue, surgery, 
radiotherapy and immunotherapy [1, 4]. Despite decades 
of considerable international efforts to improve outcome, 
long-term survival of high-risk disease remains as low as 
40% [2, 4]. Two major remaining obstacles are managing 
resistance to induction therapy, which causes progression 
and early death, and managing chemotherapy-resistant 
relapses due to minimal residual disease, which can occur 
years after initial diagnosis. MYCN amplifications [5, 6] and 
activating ALK mutations or amplifications [7–10] define, 
among other molecular aberrations, patient subgroups 
with highly aggressive and frequently therapy-resistant 
neuroblastomas. One of the first targeted treatment options 
to become available for chemoresistant neuroblastomas is 
targeting activating ALK mutations or amplifications by 
blocking ALK tyrosine kinase activity [11–15]. Therapies 
indirectly targeting MYCN are not yet under clinical 
investigation. Promising preclinical strategies include 
binding or enzymatic inhibition of epigenetically acting 
proteins such as the BRD4 bromodomain protein [16, 17], 
the EZH2 [18] or DNMT1 [19] methyltransferases or the 
histone deacetylases [20, 21], and disturbing mechanisms 
maintaining MYCN protein stability via the inhibition of 
aurora kinase A (AURKA) [22].
OMICS-based investigations of the primary biopsy 
specimen cannot currently predict which tumors will 
develop resistance to first-line therapy, meaning that 
physicians have no molecular rationale for switching from 
an ineffective first-line therapy to a potentially life-saving 
second-line therapy without losing precious time. The 
invasive nature of surgical biopsies deters their sequential 
application to monitor disease in patients with cancer. Single 
biopsies often fail to reflect cancer dynamics, intratumor 
heterogeneity and drug sensitivities likely to change during 
cancer evolution and treatment. Emerging data indicate 
that implementing molecular characterization of tumor 
surrogates such as cell-free nucleic acids [23–29], exosomes 
[30], metabolites [31], circulating and disseminated tumor 
cells [32, 33] isolated from blood, bone marrow und urine 
will improve molecular disease assessment for treatment 
selection, patient monitoring and outcome prediction 
for cancer patients. Liquid biopsies could capture the 
molecular landscape of all tumor clones, and provide a 
method to follow clonal evolution in tumor subpopulations 
and treatment response in real time. We aimed to establish 
MYCN and ALK droplet digital PCR for the routine 
assessment of copy number status from sequential 
neuroblastoma blood and bone marrow samples to assist risk 
stratification and detection of cancer progression via MYCN- 
or ALK-dependent tumor-promoting subpopulations.
RESULTS
Droplet digital PCR supports quantifiable 
MYCN copy number measurement in mixed total 
DNA lysates from neuroblastoma cells
Droplet digital PCR (ddPCR) is a highly sensitive 
recently developed technology to quantify specific gene 
regions using a limiting dilution concept (Figure 1) [34, 35]. 
We set out to evaluate ddPCR for use with patient blood 
plasma samples and determine its accuracy and sensitivity 
for detecting neuroblastoma-specific MYCN copy number 
variation in cell-free DNA (cfDNA). A 70-nucleotide 
synthetic template and a convenient primer-probe set were 
designed for ddPCR-based MYCN detection (Figure 2A). 
We serially diluted the template to produce 10, 100, 
1000 and 10,000 copies per µl H2O (Figure 2B). MYCN 
copy number was analyzed in the dilution series using 
ddPCR. The copy number detected by ddPCR perfectly 
correlated (Pearson’s correlation coefficient r = 1.00) 
with the theoretically calculated number of MYCN copies 
per µl H2O (Figure 2C). These data demonstrate that 
ddPCR detection maintains linearity within the range of 
10 to 10,000 copies per µl in the absence of background 
molecules. We next assessed ddPCR sensitivity in detecting 
MYCN amplification in a mixture of genomic DNA isolated 
from two neuroblastoma cell lines. This experimental 
design was planned to reflect the status of a heterogeneous 
tumor containing cell clones with and without a MYCN 
amplification. We titrated the number of cells from the 
Kelly cell line, which harbors a MYCN amplification, 
with the number of SK-N-AS cells, which lack MYCN 
amplification, to generate a titration series comprising two 
cellular backgrounds. We then extracted genomic DNA 
(gDNA), sheared it by sonication and measured MYCN 
copy number by ddPCR. We detected 406.67 MYCN 
copies in undiluted Kelly cells and 1.76 MYCN copies 
in SK-N-AS cells (Figure 3). The MYCN copy number 
determined by ddPCR strongly correlated (Spearman’s 
correlation coefficient r = 0.93, p = 0.0007) with the 
MYCN copy number calculated from the gDNA titration 
series using the mixed cell background. The full extent of 
MYCN amplification present in the Kelly cells could not 
be detected in the normal diploid background of SK-N-
AS cells if the gDNA mixture was diluted between 1:100 
and 1:400, however, a MYCN gain was detected at these 
dilutions (Figure 3). Dilution to 1:500 no longer detected a 
MYCN gain caused by the presence of amplified cells in the 
normal diploid background using our ddPCR protocol. Our 
data demonstrate that ddPCR detection maintains linearity 
within the range of 10 to 10,000 copies per µl in the absence 
of background molecules and that ddPCR can be reliably 
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used to detect MYCN amplification in gDNA from as little 
as one Kelly cell in a background of nine cells lacking 
MYCN amplifications. 
Droplet digital PCR yields exact MYCN and ALK 
copy numbers for 15 neuroblastoma cell lines
We selected 15 neuroblastoma cell lines previously 
reported to harbor MYCN and/or ALK amplifications, gains 
or the normal diploid chromosomal complements in the 
regions of MYCN and ALK as a panel in which to validate 
detection of gene amplification or gain by ddPCR. We 
included 1 medulloblastoma and 1 colon adenocarcinoma 
cell line, each reported to harbor a MYC amplification 
[36, 37], to test the specificity with which our ddPCR 
protocol detects MYCN. We extracted gDNA from this cell 
line panel, then sheared gDNA samples by sonication prior 
to ddPCR copy number detection. The German NB2004 
Figure 1: Schematic models of quantitative real-time and droplet digital PCR. (A) Signal detection in quantitative real-time 
PCR (qPCR) is provided in a single reaction, measured in real-time and analyzed from the exponential phase of the reaction. (B) Droplet 
digital PCR (ddPCR) reaction reagents are partitioned into ~20,000 droplets before PCR reactions proceed to the reaction plateau end point 
in individual droplets. Droplets are assessed as positive or negative from their fluorescent signal intensity. 
Figure 2: Droplet digital PCR maintains linearity over a broad copy number range. (A) Schematic representation of the 
70-nucleotide double-stranded synthetic MYCN template covering the complete sequence of the MYCN amplicon. Primers (arrows), probe 
(green line) and the positions of the FAM fluorescent dye (green dot) and BHQ1 quencher (black dot) are indicated. (B) Theoretically 
calculated numbers of MYCN copies after serial dilution of the synthetic template in H2O are shown. (C) Correlation analysis of theoretically 
calculated MYCN copies (x-axis) and copies of synthetic template assessed in dilution series using ddPCR (y-axis, as mean ± SD; n ≥ 3). 
Pearson’s correlation coefficient (r) and p-value is indicated.
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trial protocol for FISH analysis of primary neuroblastoma 
samples designates MYCN amplification as the detection 
of > 8 MYCN copies, gain as detection of 3 to 8 copies 
and ‘single-copy’ as 2 copies. We designated MYCN and 
ALK amplification for our ddPCR analyses as the detection 
of ≥ 8.01 copies, gain as detection of 2.74 to 8.00 copies 
and normal diploid as detection of 1.50 to 2.73 copies. 
The thresholds for ddPCR were statistically determined 
from our cell line data set. MYCN copy number relative 
to NAGK copy number, as a normal diploid reference 
gene, was analyzed in gDNA isolated from cell lines and 
corresponding conditioned medium, using our established 
ddPCR protocol. We confirmed the amplified status of 
MYCN in BE(2)-C, TR14, Kelly, NB-1, LAN-5, SK-N-
DZ, IMR-5 and IMR-32 reported in the literature. The 
MYCN copy numbers we determined (Figure 4, Table 1) 
from gDNA for BE(2)-C, Kelly, LAN-5 and IMR-32 were 
distinctly higher than the amplification levels reported in 
the literature using Southern blotting, FISH, competitive 
PCR, SNP oligonucleotide arrays or other methods 
(reported ranges summarized in Table 1). We determined 
276.2 ± 27.7 MYCN copies in gDNA from the NB-1 cell 
line (Figure 4, Table 1) to ascertain its amplified status, 
which was unclear from previous FISH assessments 
reporting 2 or 20 MYCN copies (Table 1). We confirmed 
a MYCN gain in the SH-SY5Y cell line that was unclear 
from the literature (2 or 3 copies, Table 1) using ddPCR 
analysis of gDNA (Figure 4, Table 1). MYCN copy 
numbers determined using ddPCR in gDNA (Figure 4, 
Table 1) confirmed the gain in LAN-6 and normal diploid 
status in the SK-N-AS, SH-EP, SK-N-FI, NBL-S and 
CLB-GA neuroblastoma cell lines, which are reported in 
the literature (Table 1). We measured 1.85 ± 0.11 MYCN 
copies in gDNA from the HD-MB03 medulloblastoma 
cell line and 1.67 ± 0.17 MYCN copies in gDNA from 
the COLO-320 colon adenocarcinoma cell line (Figure 4, 
Table 1), confirming the specificity of our ddPCR assay 
for MYCN. In conclusion, we confirmed the MYCN copy 
number status reported for most neuroblastoma cell 
lines examined in our panel, and provide evidence for a 
MYCN gain in the SH-SY5Y cell line and a strong MYCN 
amplification in the NB-1 cell line.
We analyzed ALK copy numbers relative to 
NAGK copy numbers using ddPCR of gDNA from 
our neuroblastoma cell line panel. We confirmed 
ALK amplifications in the IMR-32, NB-1 and IMR-5 
neuroblastoma cell lines, which were previously reported 
in the literature (Figure 5, Table 1). Droplet digital PCR 
detected 102.8 ± 4.3 ALK copies in the IMR-32 cell line 
to confirm a high-level amplification, where multiplex 
ligation-dependent probe amplification had previously 
detected normal diploid status and analysis by SNP 
array or arrayCGH detected an amplification or partial 
amplification of unspecified copy number, respectively 
(Table 1). The ALK copy number determined using our 
protocol (Figure 5, Table 1) for NB-1 corresponded well to 
Figure 3: MYCN copy number detection in a titration series of mixed neuroblastoma cell lines either harboring or 
lacking MYCN amplification. Kelly cells (MYCN-amplified) were titrated with SK-N-AS cells (diploid MYCN) to generate the indicated 
titration series. Genomic DNA was extracted and fragmented by sonication before MYCN copy number was assessed in 2 ng gDNA using 
ddPCR (green bars, mean ± SD; n ≥ 3). The number of MYCN copies calculated to be present at each titration step are shown by the white bars. 
Dashed lines indicate the thresholds used for FISH analysis of the neuroblastoma biopsy in the German NB2004 trial protocol: diploid MYCN 
(2 copies), MYCN gain (≥ 3 copies) and MYCN amplification (> 8 copies). Target gene copy number was analyzed using QuantaSoft analysis 
software (version 1.7.4, Bio-Rad). This software determined the copy number by calculating the ratio of the target molecule concentration 
A (copies/µl) to the reference molecule concentration B (copies/µl) times the number of reference species copies NB in the human genome 
(  )B
Acopy number N
B
= ×
.
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the amplification level assessed by Southern blotting (30– 
40 copies) reported in the literature (Table 1). The level 
of ALK amplification has not been previously quantified 
for IMR-5 (Table 1), which we show harbors 132.8 ± 3.3 
ALK copies (Figure 5, Table 1). ALK gains were detected 
in the BE(2)-C, Kelly, LAN-6 and SH-SY5Y cell lines 
using our ddPCR protocol (Figure 5, Table 1). Our data 
specifically confirm the ALK gain in SH-SY5Y that was 
unclear from the literature (2 or 3 copies, Table 1). In 
contrast, our ddPCR data contradicted previous reports 
of normal diploid ALK in the BE(2)-C, Kelly and LAN-6 
cell lines (Table 1). We confirmed normal diploid status of 
ALK in the TR14 cell line (Figure 5, Table 1), which was 
unclear from previous studies reporting either amplified or 
normal diploid ALK status (Table 1). We also confirmed 
normal diploid ALK status (Figure 5, Table 1) in the 
SK-N-AS, SH-EP, LAN-5, NBL-S, SK-N-DZ, SK-N-FI 
and CLB-GA cell lines, which was previously reported 
(Table 1). We provide exact ALK copy number data for 
our neuroblastoma cell line panel that adds to previous 
reports classifying them only as diploid or amplified, and 
confirmed the reported ALK status with 6 exceptions. We 
provide evidence for the diploid status of ALK in the TR14 
cell line, ALK gains in the BE(2)-C, Kelly, SH-SY5Y and 
LAN-6 cell lines and a strong ALK amplification in the 
IMR-32 cell line.
MYCN and ALK copy number can be reliably 
determined from conditioned medium
As an initial step towards copy number detection in 
acelluar biosamples such as blood plasma, we analyzed 
MYCN and ALK amplification status from cfDNA in 
medium conditioned by neuroblastoma, medulloblastoma 
and colon adenocarcinoma cell lines. The copy numbers 
detected using cfDNA in our ddPCR protocol were 
compared with copy numbers determined from cellular 
gDNA. We purified cfDNA from medium conditioned 
by our cell line panel. The MYCN amplifications we 
detected using ddPCR of gDNA in 8 neuroblastoma 
cell lines ranged from the 86.0 ± 6.4 MYCN copies 
measured in IMR-32 cells to the 510.0 ± 73.9 MYCN 
copies measured in BE(2)-C cells (Figure 4, Table 1), 
and all 8 amplifications could also be deduced from 
cfDNA. MYCN amplifications at the levels of 68 MYCN 
copies for IMR-32 and 505 MYCN copies for BE(2)-C 
were ascertained from cfDNA, which corresponded well 
with copy numbers determined from gDNA (Figure 4, 
Table 1: MYCN and ALK copy numbers determined by ddPCR for established cell lines from 
cellular genomic DNA and conditioned medium-derived cell-free DNA
MYCN copy numbera ALK copy numbera
Cell line genomic DNA cell-free DNA
genomic DNA 
in literatureb genomic DNA cell-free DNA
genomic DNA 
in literatureb
BE(2)-C 510.0 ± 73.9 505.0 50c –120c [39, 66] 4.28 ± 0.06 4.25 2 [77]
TR14 478.0 ± 77.1 308.0 120 [41] 1.93 ± 0.05 2.49 2-ampl. [12, 57]
Kelly 406.7 ± 49.3 339.8 ± 80.4 100c –240c [38, 39, 66] 3.05 ± 0.30 3.22 ± 0.17 2 [7, 77]
NB-1 276.2 ± 27.7 241.5 2 –20 [8, 42] 44.3 ± 2.4 56.7 30-40 [8, 15, 57]
LAN-5 204.8 ± 33.0 204.0 50c –150c [38, 40] 2.06 ± 0.07 2.26 2 [12, 57]
SK-N-DZ 130.2 ± 2.0 129.0 ± 22.6 10c [67] 2.09 ± 0.09 2.25 ± 0.16 2 [7]
IMR-5 112.3 ± 6.8 93.0 ampl. [68] 132.8 ± 3.3 139.0 ampl. [7]
IMR-32 86.0 ± 6.4 68.0 15c –75c [38, 40, 41, 66] 102.8 ± 4.3 87.5 2-ampl. [12, 57, 76]
SH-SY5Y 3.02 ± 0.11 3.27 ± 0.01 2–3 [69-72] 3.04 ± 0.06 2.74 ± 0.08 2-3 [57, 71]
LAN-6 2.79 ± 0.13 2.77 3 [73] 3.01 ± 0.14 3.40 2 [57]
CLB-GA 2.21 ± 0.40 2.17 2 [74] 2.24 ± 0.12 2.09 2 [9, 57]
NBL-S 2.01 ± 0.08 1.98 2 [75] 2.07 ± 0.09 2.20 2 [57]
SK-N-FI 1.99 ± 0.22 1.70 2 [75] 2.15 ± 0.16 1.57 2 [12, 57]
SH-EP 1.89 ± 0.24 1.67 ± 0.12 2 [39] 1.97 ± 0.17 1.87 ± 0.18 2 [57]
SK-N-AS 1.76 ± 0.11 2.12 ± 0.05 2 [39] 1.92 ± 0.06 1.81 ± 0.05 2 [7, 12, 57]
HD-MB03d 1.85 ± 0.11 1.79 2 [36] - - -
COLO-320d 1.67 ± 0.17 2.00 2 [5] - - -
acopy numbers as mean ± SD (genomic DNA, n ≥ 3 and cell-free DNA, n ≥ 1)
bFor comparison, the MYCN and ALK values reported in the literature were included.
camplification (fold)
dcontrol cell lines lacking MYCN amplification and harboring MYC amplifications
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Table 1). Absolute MYCN copy numbers determined from 
cfDNA and gDNA were identical for LAN-5 and SK-N-
DZ. Absolute MYCN copy numbers determined for the 
TR14 cell line from cfDNA varied most strongly, with 
308 copies detected in cfDNA and 478.0 ± 77.1 copies 
determined from cellular gDNA (Figure 4, Table 1). Our 
ddPCR assessment of cfDNA from the SH-SY5Y cell 
line also confirmed the MYCN gain detected in gDNA 
(Figure 4, Table 1). Likewise, the MYCN gain detected 
in the LAN-6 cell line was detectedin cfDNA (Figure 4, 
Table 1). The MYCN normal diploid status detected using 
gDNA was confirmed using cfDNA for the neuroblastoma 
cell lines, CLB-GA and SK-N-AS, as well as the MYC-
amplified medulloblastoma and colon adenocarcinoma cell 
lines used as controls for MYCN assay specificity (Figure 
4, Table 1). The MYCN copy numbers we measured 
in conditioned medium-derived cfDNA significantly 
correlated (Spearman’s correlation coefficient r = 0.9314) 
with the copy numbers detected in corresponding cellular 
gDNA for all 17 cell lines assessed (Figure 6A). Taken 
together, our data show that our ddPCR protocol can 
clearly distinguish between MYCN amplification, gain and 
normal diploid status in cell lines using medium-derived 
cfDNA. 
We further validated copy number detection by 
ddPCR of cfDNA using our assay for ALK copy number 
in our neuroblastoma cell line panel. ALK copy numbers 
determined using cfDNA from the IMR-5, IMR-32 and 
NB-1 cell lines were close to the values determined from 
gDNA (Figure 5, Table 1), and showed that high-level 
ALK amplifications could also be detected using cfDNA. 
ALK copy numbers determined from cfDNA confirmed 
the ALK gains we detected in gDNA. Absolute ALK copy 
numbers determined from cfDNA from the BE(2)-C, 
Kelly, SH-SY5Y and LAN-6 cell lines corresponded well 
to those determined from gDNA (Figure 5, Table 1). ALK 
diploid status was also confirmed in all neuroblastoma 
cell lines using cfDNA. Absolute ALK copy numbers 
determined using cfDNA from the CLB-GA, SK-N-DZ, 
SH-EP and SK-N-AS cell lines corresponded well to 
those determined from gDNA (Figure 5, Table 1). ALK 
copy number determined for the TR14 cell line from 
cfDNA was slightly higher than the 1.93 ± 0.05 ALK 
copies determined from gDNA, but is still designated as 
normal diploid according to our ddPCR thresholds (Figure 
5, Table 1). ALK copy numbers detected using cfDNA 
also significantly correlated (Spearman’s correlation 
coefficient r = 0.8143) with copy numbers measured in 
corresponding gDNA from all 15 neuroblastoma cell lines 
assessed (Figure 6A). These results further validate the 
accurate detection of gene copy number using cfDNA 
derived from conditioned medium for assessment of ALK 
amplification, gain and diploid status. 
Because MYCN (2p24.3) and ALK (2p23.2-
2p23.1) are both located on chromosome 2p, we 
assessed the extent of correlation between MYCN and 
Figure 4: Comparison of absolute MYCN copy numbers determined by ddPCR for neuroblastoma cell lines. Genomic 
DNA was extracted from cultured cells and fragmented by sonication before ddPCR for MYCN copy number (white circles, mean indicated 
by the line and SD indicated by the whiskers; n ≥ 3). Cell-free DNA was purified from medium conditioned by the cell lines, and MYCN 
copy number was determined by ddPCR (green squares, mean indicated by the line and SD indicated by the whiskers; n ≥ 1). The MYC-
amplified HD-MB03 medulloblastoma [36] and COLO-320 colorectal carcinoma [5] cell lines were used as controls. Dashed lines indicate 
the thresholds used for FISH analysis of the neuroblastoma biopsy in the German NB2004 trial protocol: diploid MYCN (2 copies), MYCN 
gain (≥ 3 copies) and MYCN amplification (> 8 copies).
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ALK copy numbers. Plotting the MYCN copy numbers 
against corresponding ALK copy numbers divided our 
15-cell line panel into 6 groups based on combined 
MYCN and ALK status (Figure 6B). One group contains 
neuroblastoma cell lines with normal diploid status of 
both genes (SK-N-AS, SH-EP, NBL-S, SK-N-FI and 
CLB-GA). The LAN-6 and SH-SY5Y cell lines belong 
to a second group harboring gains in both MYCN and 
ALK, indicating a larger region containing both genes 
may have been gained during a single event. MYCN-
amplified cell lines were distributed within different 
groups according to their ALK status. The SK-N-DZ, 
LAN-5 and TR14 cell lines maintained their ALK 
diploid status in combination with MYCN amplification. 
The Kelly and BE(2)-C cell lines acquired ALK gains 
in addition to MYCN amplification, indicating separate 
events driving MYCN and ALK aberrations in these 
cell lines. The IMR-32 and IMR-5 cell lines harbor 
approximately equal ALK and MYCN copy numbers, 
and the NB-1 cell line harbors many more MYCN 
than ALK copies (Figure 6B, Table 1) indicating a 
single-event and multi-event mechanism creating the 
copy number landscape for MYCN and ALK in these 2 
groups, respectively. Interestingly, no cell line harbored 
an ALK gain or amplification without a MYCN gain or 
amplification. Our ddPCR data from cell lines provide 
mechanistic insights into gain or amplification of 
regions on chromosome 2p in neuroblastoma.
Plasma collected from mice harboring 
xenografts and from patients reflects tumor 
MYCN and ALK copy number status
To initially test ddPCR detection capabilities 
in context with blood plasma, we compared MYCN 
and ALK copy numbers in xenograft tumors growing 
subcutaneously in mice with those measured in cfDNA 
isolated from mouse blood plasma, thereby avoiding 
the dilution effect potentially arising from damaged 
human white blood cells. Neuroblastoma cells were 
subcutaneously injected into both flanks of 3 NMRI-
Foxn1nu mice for the analysis of MYCN and ALK, and 
the mouse cohorts monitored until the largest xenograft 
tumor reached a tumor volume of 1500 mm³ at day 
40 (Figure 7A). Xenografts were established from a 
neuroblastoma cell line, named OHC-NB1 and established 
by our group (unpublished data), that harbors a high-
level MYCN amplification and normal diploid ALK. As 
the positive control for tumor copy number, gDNA was 
extracted from each xenograft tumor and sonicated for 
ddPCR. Total blood plasma was collected from 3 mice by 
orbita puncture and pooled for cfDNA isolation. MYCN 
and ALK copy numbers were assessed in the cfDNA 
isolated from the plasma pooled using ddPCR. Our 
ddPCR protocol detected 139.75 MYCN copies in plasma-
derived cfDNA, which was similar to the copy number 
(177.50 ± 19.81) determined from xenograft tumor gDNA 
Figure 5: Comparison of absolute ALK copy numbers determined by ddPCR for neuroblastoma cell lines. Genomic 
DNA was extracted from cultured cells and fragmented by sonication before ALK copy number was determined by ddPCR (white circles, 
mean indicated by the line and SD indicated by the whiskers; n = 3). Cell-free DNA was purified from medium conditioned by the cell lines, 
and copy numbers were detected by ddPCR (blue squares, mean indicated by the line and SD indicated by the whiskers; n ≥ 1). Dashed lines 
indicate thresholds for diploid (2 copies), gain (≥ 3 copies) and amplified (> 8 copies) status. 
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(Figure 7B). ALK copy number was also assessed in both 
plasma-derived cfDNA and tumor gDNA using ddPCR. 
We detected 2.00 ALK copies using plasma-derived 
cfDNA, which was within the error range of the ALK 
copy number (2.06 ± 0.02) detected in the tumor gDNA. 
Our ddPCR protocol accurately detected the ALK normal 
diploid status and amplified MYCN status of the xenograft 
tumor from mouse blood plasma. These data demonstrate 
that cfDNA is released by subcutaneously grown human 
tumor cells into the mouse bloodstream in sufficient 
quantity to calculate tumor cell gene copy number from 
blood plasma, and confirm proof-of-principle for using our 
ddPCR protocol to detect ALK and MYCN copy numbers 
from patient blood plasma samples. 
We next evaluated ddPCR-based MYCN and 
ALK copy number assessment in blood plasma 
samples retrospectively collected at diagnosis from 10 
neuroblastoma patients with known MYCN status. For 
comparison MYCN and ALK copy number assessment 
was performed in blood plasma samples collected from 16 
healthy individuals. The German Neuroblastoma Biobank 
(Cologne) provided blood plasma samples paired with 
genomic DNA from the corresponding primary tumor 
from patients treated within the German NB2004 trial. 
Fragmentation of tumor gDNA was achieved by direct 
enzymatic digestion in the ddPCR reaction mixture 
due to the low DNA concentration in the 20 µl samples 
provided in water, and cfDNA was purified from the 
plasma samples before ddPCR. MYCN and ALK copy 
numbers were analyzed using our ddPCR protocol in the 
matched gDNA and cfDNA patient samples as well as 
in the cfDNA samples from healthy individuals. MYCN 
copy number in cfDNA samples from healthy individuals 
ranged between 1.54 to 2.60, and ALK copy number was 
between 1.64 and 2.50 (Table 3), indicating in line with 
the thresholds set a normal diploid status in all samples 
analyzed. FISH analysis conducted on the primary tumor 
for staging at diagnosis was used as the reference for 
MYCN status. We measured MYCN copy numbers in the 
range of 1.70 to 2.16 in tumor gDNA from patients 1–5 
using ddPCR, which were in complete accordance with 
the diploid MYCN status determined by FISH (Figure 8A, 
Table 2). MYCN copy numbers ranging from 73.5 to 
267.0 were detected using ddPCR of tumor gDNA from 
patients 6–10 (Figure 8A, Table 2), who were diagnosed 
with MYCN-amplified neuroblastomas according to 
FISH. MYCN copy numbers detected by ddPCR were 
higher than the amplification levels determined by FISH 
for each tumor. Copy numbers determined by ddPCR 
discriminated between a range of 73.5 to 129.0 for the 
20- to 30-fold MYCN amplification levels determined 
by FISH and a range of 207.5 to 267.0 for the 50-fold 
MYCN amplification levels. MYCN copy numbers detected 
using plasma-derived cfDNA significantly correlated 
(Spearman’s correlation coefficient r = 0.8182) with the 
copy numbers measured in tumor gDNA (Figure 8C). 
We measured slightly higher MYCN copy numbers using 
plasma-derived cfDNA than the corresponding tumor 
gDNA for patients 2, 3 and 5 (Figure 8A, Table 2). 
MYCN copy numbers determined using plasma-derived 
Figure 6: MYCN and ALK copy numbers determined by ddPCR of genomic DNA correlate with copy numbers 
determined from the corresponding cell-free DNA. (A) Copy numbers determined by ddPCR from genomic DNA from each cell 
line is plotted on the x-axis and copy numbers determined by ddPCR from the corresponding cell-free DNA isolated from conditioned 
medium is plotted on the y-axis. Values presented in Figures 4 and 5 were used. Significance of the correlation between the 2 DNA sources 
for determining MYCN (black circles) and ALK (white circles) copy numbers was assessed from the plot, and the Spearman correlation 
coefficient (r) and p-value are indicated. Dashed lines indicate the position of diploid gene status. (B) Plotting MYCN copy numbers against 
corresponding ALK copy numbers divided neuroblastoma cell lines into different groups based on combined copy number status. MYCN 
copy numbers determined by ddPCR from genomic DNA from the indicated cell lines are plotted along the y-axis against ALK copy 
numbers determined by ddPCR from genomic DNA from the same cell lines (x-axis). Same values as those plotted in A are used. Dashed 
lines indicate the position of diploid gene status.
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Table 2: MYCN and ALK copy numbers determined by ddPCR from neuroblastoma patient blood 
plasma samples and paired genomic DNA from the corresponding primary tumor biopsy
MYCN copy number ALK copy number
Patient genomic DNA
(tumor biopsy)
cell-free DNA
(plasma)
reference valuea
(tumor biopsy)
genomic DNA
(tumor biopsy)
cell-free DNA
(plasma)
reference valueb
 (tumor biopsy)
1 1.70 7.30 diploid 2.09 2.30 -
2 1.73 2.65 diploid 2.10 2.00 diploid
3 1.93 2.60 diploid 2.09 1.88 diploid
4 2.14 5.10 diploid 2.20 2.10 -
5 2.16 2.70 diploid 2.02 2.80 diploid
6 85.0 60.5 20x amplified 2.00 2.19 diploid
7 129.0 37.2 20x amplified 2.19 3.20 -
8 73.5 13.5 30x amplified 2.13 3.50 -
9 207.5 49.2 50x amplified 3.40 3.07 -
10 267.0 83.0 50x amplified 2.04 2.13 -
aFISH
bFISH or qPCR
Figure 7: MYCN and ALK copy numbers assessed in cell-free DNA from plasma reflect copy numbers determined 
from xenograft tumor genomic DNA. (A) Schematic workflow summarizing xenografting of the OHC-NB1 neuroblastoma cell line 
and sample preparation from genomic DNA (gDNA) and cell-free DNA (cfDNA) for droplet digital PCR (ddPCR). OHC-NB1 cells were 
subcutaneously injected into both flanks of 3 NMRI-Foxn1nu mice for gene copy number determination. Genomic DNA was extracted 
from each xenograft tumor and fragmented by sonication prior to ddPCR. Total blood plasma from the 3 mice was pooled for cfDNA 
isolation. (B) White bars show MYCN and ALK copy numbers detected by ddPCR using xenograft tumor genomic DNA (mean ± SD; n = 6) 
as the reference base. MYCN (green bar) and ALK (blue bar) copy numbers detected by ddPCR of cell-free DNA isolated from pooled 
mouse plasma (n = 1) are shown.
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cfDNA were distinctly higher than those determined 
from corresponding tumor gDNA for patients 1 and 4, 
respectively (Figure 8A, Table 2). MYCN copy numbers 
from plasma-derived cfDNA were consistently lower than 
the corresponding tumor gDNA from patients 6–10 with 
MYCN-amplified tumors (Table 2). ALK copy numbers 
determined using either plasma-derived cfDNA or tumor 
gDNA revealed normal diploid status in the samples from 
patients 1–4, 6 and 10 (Figure 8B, Table 2). Tumor gDNA 
from patients 5, 7 and 8 also revealed ALK diploid status, 
however, corresponding plasma-derived cfDNA indicated 
an ALK gain in these patients (Figure 8B, Table 2). An 
ALK gain of 3.40 and 3.07 copies was detected using 
tumor gDNA and plasma-derived cfDNA, respectively, 
from patient 9 (Figure 8B, Table 2). ALK gains were 
detected using plasma-derived cfDNA from 3 of 5 
patients with MYCN-amplified tumors (patients 7, 8 and 
9), but a possible ALK gain in a tumor with diploid MYCN 
status was only detected in patient 5 (Table 2). ALK copy 
numbers assessed using ddPCR of tumor gDNA from 
patients 2, 3, 5 and 6 were in complete accordance with 
the diploid ALK status determined by FISH or qPCR 
(Table 2). The copy numbers determined from plasma-
derived cfDNA also confirmed the diploid ALK status 
in patients 2, 3 and 6, whereas plasma-derived cfDNA 
indicated an ALK gain in patient 5 (Figure 8B, Table 2). 
ALK copy numbers detected in plasma-derived cfDNA 
did not correlate (Spearman’s correlation coefficient r = 
0.2553) with the copy number determined using tumor 
gDNA (Figure 8D). This is likely because of the narrow 
range of copy number (very near to 2 in most cases) 
values obtained for a small number of patients. These 
data indicate that our ddPCR protocol accurately assessed 
ALK copy numbers using plasma-derived cfDNA and 
tumor gDNA. Our ddPCR protocol enabled the detection 
of slight ALK copy number differences between cfDNA 
and gDNA. Our results for this 10-patient pilot cohort 
utilizing only archived tumor and blood plasma samples 
demonstrate that ddPCR analysis of either tumor gDNA or 
plasma-derived cfDNA accurately distinguished between 
MYCN-amplified and normal diploid status determined by 
FISH. Our ddPCR protocol required only 2 ng of tumor 
DNA, and assessed MYCN copy number more precisely 
than FISH over a wide copy number range. Plasma-
derived cfDNA also produced MYCN copy numbers that 
correlated well with those determined from tumor gDNA. 
DISCUSSION
Here, we present ddPCR as an accurate method to 
assess MYCN and ALK copy numbers in tumor-derived 
cfDNA from blood plasma from neuroblastoma patients. 
The ddPCR method is highly sensitive and linear over a 
wide copy number range, and accurately discriminates 
between amplified, gain and normal diploid status. We 
validated our protocols in a panel of 15 neuroblastoma 
cell lines and 2 MYC-amplified non-neuroblastoma cell 
lines to control for assay specificity, and reveal evidence 
for different MYCN or ALK status than previously reported 
for 7 cell lines commonly used in research. Our ddPCR 
protocol yields absolute gene counts, making it easier to 
discriminate between gains and diploid status. We also 
Table 3: MYCN and ALK copy numbers determined by ddPCR in blood plasma samples from 16 
healthy individuals
MYCN copy number ALK copy number
Healthy individual cell-free DNA (plasma) cell-free DNA (plasma)
1 1.73 1.93
2 2.40 1.72
3 1.79 2.10
4 1.72 2.16
5 1.59 2.17
6 1.90 2.10
7 1.77 1.84
8 2.23 1.97
9 1.80 2.22
10 2.60 2.40
11 1.90 2.00
12 1.54 1.72
13 1.70 2.50
14 2.00 1.74
15 1.70 1.70
16 2.06 1.64
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Figure 8: Droplet digital PCR accurately assesses MYCN and ALK copy numbers from neuroblastoma patient 
plasma and the corresponding primary tumor biopsy. MYCN (A) and ALK (B) copy numbers were determined by ddPCR from 
retrospectively collected biomaterial samples from 10 neuroblastoma patients. Black bars show numbers determined from genomic DNA 
isolated from the tumor biopsy (single measurements). Red bars show values determined from cell-free DNA in the corresponding 200 µl 
plasma sample (single measurements). MYCN and ALK status determined at diagnosis (shown below bar graphs in A and B) were provided 
from patient records and were determined by FISH or qPCR (indicated) analysis. Dashed lines indicate the thresholds used for FISH 
analysis of the neuroblastoma biopsy in the German NB2004 trial protocol: diploid MYCN (2 copies), MYCN gain (≥ 3 copies) and MYCN 
amplification (> 8 copies). Correlation analysis of copy numbers determined from plasma-derived cell-free DNA (y-axis) and tumor biopsy 
genomic DNA (x-axis) is shown for MYCN (C) and ALK (D). Spearman correlation coefficients (r) and p-values are indicated.
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validated our protocol in the mouse xenograft model, and 
demonstrate that MYCN and ALK copy numbers could 
be accurately determined from cfDNA in human blood 
plasma. 
Gene copy number assessment using ddPCR is 
calculated through detection of the absolute concentration 
of target sequences and the diploid reference gene 
[34]. Droplet digital PCR has been used to assess gene 
copy numbers for cell lines and was compared to other 
methods used in published reports. MET copy number 
has been assessed in gDNA from gastric cancer and 
hepatocellular carcinoma cell lines and formalin-fixed, 
paraffin-embedded tumor samples from patient-derived 
xenograft models using ddPCR and SNP array or FISH 
[43]. The authors detected a significant correlation of copy 
numbers assessed using ddPCR and SNP arrays in cell 
lines or FISH in tumor samples. Belgrader and colleagues 
analyzed HER2 copy numbers in gDNA from archived 
formalin-fixed, paraffin-embedded breast carcinoma 
samples using ddPCR or FISH [44]. They confirmed 
complete concordance of ddPCR and FISH for correct 
assessment of HER2 amplifications. We demonstrated that 
ddPCR detection maintains linearity within a range of 10 
to 10,000 copies per µl in dilution series using a synthetic 
MYCN template. These data confirm previous reports of 
ddPCR linearity within a range of 1 to ~20,000 copies 
measuring HER2 and reference gene CEP17 in a dilution 
series of gDNA from the SK-BR-3 breast cancer cell line 
in H2O [45]. The concentration range of 10 to 10,000 
copies per µl covered the absolute concentrations of each 
target sequence assessed for MYCN, ALK and NAGK in 
our cell line panel analyses, indicating the reliability of the 
copy number calculations.
We assessed or re-assessed MYCN and ALK copy 
numbers in gDNA from a panel of 15 cell lines commonly 
used in neuroblastoma research during the development 
and validation of our ddPCR protocol. We provide exact 
ALK copy numbers for our neuroblastoma cell line panel 
and our protocol confirmed the amplified, gain or diploid 
status in most cell lines. While our protocol confirmed the 
amplified, gain or diploid status of MYCN in most of the 
cell lines, absolute copy numbers determined by ddPCR 
were higher than reported values determined by different 
methods. Published estimates of MYCN amplification 
also varied in reports using the same or different methods. 
We determined 406.7 MYCN copies in gDNA from the 
Kelly cell line. A range of 100 – 120 MYCN copies were 
reported for the Kelly cell line using Southern blotting 
[38], while using competitive PCR detected 240 MYCN 
copies [39]. The IMR-32 cell line was reported to harbor 
a 15-25-fold MYCN amplification using Southern blotting 
[38], 25–75 MYCN copies using Southern blotting [40] or 
50 MYCN copies using a SNP oligonucleotide array [41]. 
We assessed 86.0 MYCN copies in IMR-32 using ddPCR. 
The NB-1 cell line was reported as diploid for MYCN [8] 
or as MYCN-amplified with 20 copies estimated by FISH 
[42]. We confirmed MYCN amplification in the NB-1 
cell line, which we show harbors 276.2 MYCN copies. 
The absolute quantitation of the NAGK reference gene 
provides the normal input DNA level and functioned as 
a control in our analyses. We avoided continuous culture 
of cell lines to reduce the risk of genomic alterations 
during maintenance, and think it is unlikely that the higher 
copy numbers are produced by additional chromosomal 
alterations acquired during culture. These data indicate 
that ddPCR can be reliably used as an accurate tool to 
assess copy number over a broad range as shown by our 
reported values for MYCN and ALK in 15 established 
neuroblastoma cell lines.
Single tumor biopsies do not adequately 
reflect clonal heterogeneity within the primary tumor 
(intratumoral heterogeneity), heterogeneity between 
different tumors or metastases in the same patient or 
changes in the tumor or metastases occurring during the 
course of treatment or progression. Spatial and temporal 
heterogeneity have been described for several cancer 
entities, including colorectal cancer [46], breast cancer 
[47], glioblastoma [48] and neuroblastoma [49–51]. We 
assessed MYCN and ALK copy numbers from archived 
single tumor biopsies from the 10-patient pilot cohort 
in this study as the control measure for copy number 
detection using the paired plasma samples. For some 
patients, tumor gDNA and plasma-derived cfDNA yielded 
different gene copy numbers. Copy numbers assessed 
using cfDNA indicated a gain for MYCN in 2 patients (1 
and 4) and for ALK in 3 patients (5, 7 and 8), whereas 
corresponding tumor gDNA revealed normal diploid 
status. The higher copy numbers detected in tumor-
derived circulating cfDNA may indicate more aggressive 
tumor clones either in the primary tumor or at metastatic 
sites that were not sampled by the single primary tumor 
biopsy. Large-scale longitudinal studies monitoring 
MYCN and ALK copy number status in cfDNA from 
individual patients and comparing these findings with 
the in-depth analysis of all tumor specimens collected 
from the respective patients are required to ultimately 
define the potential of cfDNA analysis in context with the 
identification and characterization of tumor heterogeneity 
in metastatic neuroblastoma disease. In all patients with 
a MYCN-amplified neuroblastoma, MYCN copy numbers 
determined using cfDNA were lower than those determined 
from tumor gDNA. The lower copy numbers detected 
in tumor-derived circulating cfDNA could be due to the 
dilution effect by damaged white blood cells generated 
through the suboptimal pre-analytic handling of the 
respective blood samples, which were as stated elsewhere 
originally not collected for cfDNA studies. Alternatively, 
this finding could reflect clonal tumor heterogeneity in 
the primary tumor, and be an average of the biopsied 
amplified clonal region and other non-amplified regions. 
Again, large-scale trials monitoring disease status by 
optimally collecting and analyzing blood and tumor tissue 
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samples are needed to ultimately answer this question. 
The potential for detection of tumor heterogeneity using 
cfDNA has been suggested in several reports. Chicard 
and colleagues compared tumor genome copy number 
profiling of cfDNA using the OncoScan array and array 
CGH analysis of the primary neuroblastoma biopsy [51]. 
They identified TERT alterations, which are associated 
with aggressive high-risk neuroblastoma [52, 53], only 
in tumor-derived cfDNA (not tumor biopsy) from 2 
patients. The authors hypothesized that cfDNA might 
reflect genetic alterations of more aggressive cell clones 
[51]. Our detection of MYCN gains in patients 1 and 4, and 
ALK gains in patients 5, 7 and 8 in plasma compared to the 
primary tumor biopsy also indicated these patients have 
subclonal amplifications in the primary tumor, which were 
not at the site of biopsy or present in distant undetected 
metastases. Sequence analysis of plasma-derived cfDNA 
detected all mutations detected in the primary tumor and/
or its synchronous liver metastasis in a massive parallel 
sequencing study of samples from a patient with breast 
carcinoma [54]. Similarly, Chan and colleagues detected 
a composite pattern of specific copy number aberrations 
and mutations in plasma-derived cfDNA from a patient 
that corresponded to the breast carcinoma and 2 ovarian 
tumors synchronously present using massive parallel 
sequencing [55]. These data, although incidental, strongly 
support that differing copy numbers in cfDNA and tumor 
gDNA indicate the presence of tumor cell populations 
in the patient that are not captured by the single primary 
tumor biopsy. We conclude that this interpretation applies 
without restriction for the MYCN gains detected in plasma 
from patients 1 and 4, and the ALK gains detected in 
plasma from patients 5, 7 and 8 in our cohort. Even though 
our pilot cohort only includes 10 patients, it is astounding 
to speculate that single primary tumor biopsies may be 
underestimating the real tumor cell population in half of 
high-risk neuroblasoma patients.
Since retrospectively collected patient samples 
were analyzed in this study, blood was not sampled 
according to a standardized protocol for cfDNA 
detection. Blood samples may have spent longer than 
a day at room temperature before plasma preparation 
and storage at -80°C. Lysis of white blood cells before 
cfDNA preparation can dilute the tumor-derived DNA 
with normal cellular DNA. This dilution effect was 
previously demonstrated by titrating serum samples with 
increasing numbers of white blood cells, which masked 
high MYCN/NAGK ratios and prevented detection of 
MYCN amplification above a threshold [24]. We also 
simulated a dilution effect by titrating MYCN-amplified 
Kelly cells with SK-N-AS cells harboring the normal 
diploid MYCN complement, and showed that detection of 
the MYCN amplification was masked above a threshold 
of dilution with 99 normal diploid cells. This effect 
depends on both amplification level and degree of dilution. 
Visible hemolysis had occurred in plasma samples from 
4 neuroblastoma patients (2, 6, 8 and 10), indicating that 
white blood cells may have also lysed in these samples. 
The lower copy numbers detected in plasma samples from 
patients with MYCN-amplified tumors could have resulted 
from dilution with gDNA from lysed normal blood cells. 
Although, we did not detect copy numbers closer to the 
tumor biopsy in the two plasma samples that lacked visible 
hemolysis (patients 7 and 9). Dilution may have reduced 
the copy numbers determined from all our plasma samples, 
which were collected under suboptimal conditions for 
cfDNA detection. These data emphasize the importance 
of a standardized protocol for blood sampling and plasma 
preparation (limiting time at room temperature) in the 
development of cfDNA-based diagnostic protocols for 
clinical application.
A review of the literature indicates that assessment 
of MYCN status using quantitative real-time PCR and 
serum/plasma-derived cfDNA presents a promising 
method to analyze neuroblastoma patient samples. 
Serum-based MYCN analysis has been shown capable 
of separating patients into groups with amplified and 
non-amplified tumors [24, 26]. Assay sensitivity was 
dependent on neuroblastoma stage, and was highest 
in metastasized disease [25]. MYCN copy number 
detection in tumor-derived cfDNA from plasma samples 
taken before and after surgery has been suggested as 
a useful evaluation step for surgery and neoadjuvant 
chemotherapy [26]. Kurihara and colleagues analyzed 
plasma-derived cfDNA from patients with a variety of 
childhood solid tumors before and after surgery using 
next-generation sequencing and ddPCR for mutations, 
deletions or amplifications, including MYCN status in 
neuroblastomas [27]. They confirmed the potential of 
cfDNA screening using next-generation sequencing 
and ddPCR for biomarker detection. Here, we also 
accurately distinguished between MYCN-amplified and 
MYCN diploid status in tumors using plasma-derived 
cfDNA. Taken together, these results justify molecular 
disease characterization using tumor-derived cfDNA 
in blood for longitudinal monitoring of patients with 
neuroblastoma. 
A major challenge for tumor cfDNA analysis is the 
extremely low amount of circulating cfDNA present in 
blood in at least some patients [56]. Higher sensitivity 
and a requirement for lower absolute cfDNA amounts 
has been demonstrated for ddPCR in comparison with 
next-generation sequencing [56]. We have pursued 
ddPCR as the more suitable technology for repeated 
target gene copy number assessement in longitudinal 
measurements. ALK amplification is reported in 2–5% 
of primary neuroblastomas [7, 57–59]. It occurs almost 
exclusively with MYCN amplification, and has been 
detected in 7–15% of MYCN-amplified neuroblastomas 
[10, 60]. ALK gain was reported to occur in ~15–20% 
of primary neuroblastomas [57, 58]. ALK copy numbers 
detected by ddPCR of plasma-derived cfDNA have not 
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yet been reported for patients with neuroblastomas. 
We accurately assessed ALK copy numbers in the 
primary neuroblastomas from tumor-derived cfDNA 
in blood plasma samples. We detected ALK gains in 
4 plasma samples, one of which was confirmed in the 
corresponding tumor sample. Contradictory reports 
of the association of ALK amplification or gain with 
survival have been published. ALK amplification is 
strongly associated with high-risk neuroblastoma and an 
inferior outcome, and multivariate analysis suggested an 
independent influence on survival for both ALK gain and 
amplification in a cohort of 1596 neuroblastoma samples 
enrolled in a COG biology study [61]. In contrast, 
ALK amplification was not a statistically independent 
marker for survival in models with MYCN, stage and 
age in a meta-analysis, combining a new series of 254 
neuroblastomas and 455 published cases from 3 other 
cohorts [57]. Wang and colleagues identified only 3 
neuroblastomas harboring ALK amplifications, all also 
harboring MYCN amplifications, in a cohort of 188 
primary neuroblastomas from a patient cohort treated at 
the Beijing Children’s Hospital [62]. ALK amplification 
correlated with a decreased overall survival, whereas 
interestingly, MYCN or ALK gain were associated with a 
better prognosis. Thus, a MYCN-independent association 
of ALK amplification with outcome remains open. The 
authors concluded that classification of MYCN and ALK 
gene copy numbers can provide a powerful prognostic 
indicator. We theorize that the combined assessment of 
MYCN and ALK copy numbers using ddPCR of plasma-
derived cfDNA during treatment and follow-up will 
improve risk assessment for patients and enable an early 
detection of relapse and metastasis. MYCN and ALK copy 
number assessment from plasma at diagnosis could also 
identify patients with possible subclonal amplifications, 
and this analysis should accompany tumor biopsy 
analyses to test its clinical predictive power for possible 
future use in treatment stratification.
This study presents ddPCR as an accurate tool to 
assess MYCN and ALK copy numbers in neuroblastoma 
cell lines, tumor samples and tumor-derived cfDNA 
in blood plasma. Our validation experiments in 
retrospective patient samples support the hypothesis that 
using tumor-derived cfDNA from patient plasma can 
improve detection of high-risk tumor subpopulations 
harboring genomic aberrations relevant for therapy 
choice and risk assessment. Analyzing cfDNA in liquid 
biopsies will enable longitudinal measurements for a 
patient, starting prior to therapy and continuing through 
treatment course and follow-up, and supporting multiple 
diagnostic and therapeutic decisions during all phases 
of care for patients with high-risk neuroblastoma. 
This approach may improve detection of MYCN and 
ALK subclonal amplifications, monitoring of disease 
progression and treatment response as well as relapse 
detection.
MATERIALS AND METHODS
Patient samples 
Matched blood plasma and tumor tissue genomic 
DNA from primary neuroblastoma biopsies were obtained 
from the German Neuroblastoma Biobank (Cologne). All 
10 neuroblastoma patients were registered in the German 
NB2004 clinical trial, and informed patient/parent consent 
was obtained during trial participation. The following 
preparatory or storage steps occurred prior to delivery of 
patient biosample residues for this study. Peripheral blood 
was stored for a minimum of 24 h, then centrifuged at 
approximately 1000 x g for 10 min before storage of the 
plasma at –80°C. The extracted tumor gDNA was stored 
at –80°C. Values for MYCN and ALK status determined 
within the NB2004 study protocol and maintained 
with patient records in the central trial database were 
communicated with the patient biomaterial samples. For 
comparison, blood plasma from 16 healthy individuals 
was collected.
Animal experiments
Subcutaneous xenografts were created by injecting 
10 × 106 OHC-NB1 cells (unpublished data) suspended in 
200 μl Matrigel (BD Biosciences, Heidelberg, Germany) 
into each flank of 3 NMRI-Foxn1nu mice. Tumor size was 
measured daily with a caliper, and volume was calculated 
by π/6(width×height×depth). Animals were sacrificed 40 
days after grafting, and total blood from orbita puncture 
in the 3 mice was collected in a single EDTA tube and 
centrifuged 7 min at 3000 x g. Plasma was centrifuged 
10 min at 3900 x g and the supernatant was stored at 
–80°C before sample preparation. Genomic DNA was 
extracted from the 6 tumors separately as reference tumor 
DNA. Animal handling and care conformed to national 
and EU regulatory standards of the Research Institutes for 
Experimental Medicine, Charité - Universitätsmedizin 
Berlin and experiments were approved by Landesamt für 
Gesundheit und Soziales Berlin.
Cell culture 
The BE(2)-C cell line was obtained from ECACC 
(Salisbury, UK) and the COLO-320, IMR-32, Kelly and 
SH-SY5Y cell lines from the DSMZ (Braunschweig, 
Germany). CLB-GA, IMR-5, LAN-5, LAN-6, NBL-S, 
SK-N-FI and TR14 were kindly provided by J.H. Schulte 
(Charité, Universitätsmedizin Berlin, Germany), NB-1 by 
I. Oehme (DKFZ, Heidelberg, Germany), SH-EP and SK-
N-AS by L. Savelyeva (DKFZ, Heidelberg), and SK-N-
DZ by A. Künkele (Charité, Universitätsmedizin Berlin). 
OHC-NB1 (unpublished data) and HD-MB03 [36] were 
established in the Deubzer laboratory. Cell line authenticity 
was validated by high-throughput SNP-based assays [63]. 
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All cell lines were cultured in full media (described in 
Supplementary Methods) at 37°C, 5% CO2, and continuous 
culture was avoided to maintain low passage numbers and 
reduce the risk of genomic alterations occurring. Cells 
for experiments were grown in short-term culture from 
low-passage stock aliquots maintained in liquid nitrogen. 
All cell lines were regularly monitored for Acholeplasma 
laidlawii and other species of mycoplasma as well as 
squirrel monkey retrovirus (SMRV) infections using high-
throughput, multiplexed testing [64]. 
Genomic and cell-free DNA isolation 
Genomic DNA was extracted from cell lines or 
xenograft tumors using the QIAamp DNA Mini kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s 
instructions. Conditioned medium (2 ml) was collected, 
centrifuged at 2000 × g for 5 min and the supernatant stored 
at –80°C. Thawed conditioned media and plasma samples 
were centrifuged at 2000 × g for 5 min to clear debris, 
then supernatant was centrifuged at 20,000 × g for 5 min. 
Cell-free DNA was purified from processed conditioned 
media, 200 µl stored human patient plasma, 1000 µl 
stored healthy individual plasma and 600 µl mouse plasma 
using the QIAamp Circulating Nucleic Acid kit (Qiagen) 
then concentrated to 50 µl using the DNA Clean and 
Concentrator-5 kit (Zymo Research, Freiburg, Germany), 
both according to manufacturers’ directions. Neuroblastoma 
gDNA was extracted using the Qiagen Puregene Core kit 
A (Qiagen) according to the manufacturer’s instructions. 
Extracted DNA samples were quantified on a Qubit 2.0 
fluorometer (Life technologies, Darmstadt, Germany). 
Purified genomic and cell-free DNA were stored at –80°C 
until MYCN and ALK copy number detection. 
Droplet digital PCR 
Genomic DNA from cell lines and xenograft tumors 
was fragmented by sonication before ddPCR. Sonication 
of gDNA from primary neuroblastoma samples was not 
possible because of the small sample volumes (20 µl), 
so fragmentation was achieved by adding 5 U of AluI 
restriction enzyme (New England Biolabs, Frankfurt/
Main, Germany) to each ddPCR reaction. The QX200 
Droplet Digital PCR System (Bio-Rad Laboratories, 
Munich, Germany) was used to simultaneously detect 
MYCN (2p24.3) or ALK (2p23.2-2p23.1) in a duplex 
reaction with the normal diploid reference gene, 
N-acetylglucosamine kinase (NAGK, 2p13.3) (2-D 
plots of the duplex reactions shown in Supplementary 
Figure 1). TaqMan ddPCR duplex reaction mixtures 
included 2x ddPCR Supermix for Probes (no dUTP) (Bio-
Rad Laboratories), each primer at final concentrations of 
900 nM and each probe at final concentrations of 250 nM 
in a total volume of 20 µl. The primers and probes used for 
MYCN and NAGK ddPCR were previously described [24], 
and are listed in Supplementary Table 1. The fluorescence 
dyes and quenchers of the MYCN and NAGK probes 
were adapted for ddPCR. ALK primers were designed 
from the amplicon described by Bavi et al. [65] and the 
ALK probe was designed with Primer3 software (http://
bioinfo.ut.ee/primer3-0.4.0/primer3/), and are listed in 
Supplementary Table 1. Reaction mixtures were loaded 
into droplet generator cartridges (Bio-Rad) together 
with 70 µl Droplet Generation Oil (Bio-Rad). Droplets 
were generated in the QX200 Droplet generator, and 
manually transferred into a 96-well PCR plate (Eppendorf, 
Hamburg, Germany) according to manufacturer’s 
recommendations. The PCR plate was heat-sealed with 
the PX1 Plate Sealer (Bio-Rad), and PCR reactions were 
performed on a T100 Thermo Cycler (Bio-Rad) with 
the following program: 1 cycle at 95°C for 10 min, 40 
cycles at 94°C for 30 seconds and at 58°C for 1 minute 
and 1 cycle at 98°C for 10 min. After PCR amplification, 
droplets were measured in the QX200 ddPCR Droplet 
Reader, and target gene copy number was analyzed using 
QuantaSoft analysis software (version 1.7.4, Bio-Rad). 
This software determined the copy number by calculating 
the ratio of the target molecule concentration A (copies/µl) 
to the reference molecule concentration B (copies/µl) 
times the number of reference species copies NB in the 
human genome copynumber
A
B
NB=





× . The double-stranded 
synthetic MYCN template for initial ddPCR testing 
was obtained from Metabion (Planegg, Germany) and 
had the sequence: 5′- GTGCTCTCCAATTCTCGCC 
TTCACTAAAGTTCCTTCCACCCTCTCCTGGGGAGC 
CCTCCTCTAGGCCATC-3′. 
Statistical analysis 
Correlation analyses were performed using 
GraphPad Prism (version 6.00). P-values below 0.05 were 
considered significant.
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